@article {Watanabe459, author = {Tomoko Watanabe and Manami Miyake and Toshinobu Shimizu and Miho Kamezawa and Naoya Masutomi and Takesada Shimura and Rikiya Ohashi}, title = {Utility of Bilirubins and Bile Acids as Endogenous Biomarkers for the Inhibition of Hepatic Transporters}, volume = {43}, number = {4}, pages = {459--466}, year = {2015}, doi = {10.1124/dmd.114.061051}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {It is useful to identify endogenous substrates for the evaluation of drug-drug interactions via transporters. In this study, we investigated the utility of bilirubins, substrates of OATPs and MRP2, and bile acids and substrates of NTCP and BSEP, as biomarkers for the inhibition of transporters. In rats administered 20 and 80 mg/kg rifampicin, the plasma levels of bilirubin glucuronides were elevated, gradually decreased, and almost returned to the baseline level at 24 hours after administration without an elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). This result indicates the transient inhibition of rOatps and/or rMrp2. Although the correlation between free plasma concentrations and IC50 values of rOatps depended on the substrates used in the in vitro studies, the inhibition of rOatps by rifampicin was confirmed in the in vivo study using valsartan as a substrate of rOatps. In rats administered 10 and 30 mg/kg cyclosporin A, the plasma levels of bile acids were elevated and persisted for up to 24 hours after administration without an elevation of ALT and AST. This result indicates the continuous inhibition of rNtcp and/or rBsep, although there were differences between the free plasma or liver concentrations and IC50 values of rNtcp or rBsep, respectively. This study suggests that the monitoring of bilirubins and bile acids in plasma is useful in evaluating the inhibitory potential of their corresponding transporters.}, issn = {0090-9556}, URL = {https://dmd.aspetjournals.org/content/43/4/459}, eprint = {https://dmd.aspetjournals.org/content/43/4/459.full.pdf}, journal = {Drug Metabolism and Disposition} }